Expression of β-tubulin isotypes in urothelial carcinoma of the bladder

World Journal of Urology

Volumn 32, Issue 2, 2014, Pages 347-352

  Choi, Jung Woo ^a   Kim, Younghye ^a   Lee, Ju Han ^a   Kim, Young Sik ^a  

^a Korea University   (South Korea)

Author keywords

Bladder cancer; Chemotherapy; Immunohistochemistry; Tubulin

Indexed keywords

BETA III TUBULIN PROTEIN, HUMAN; BETA III-TUBULIN PROTEIN, HUMAN; TUBB1 PROTEIN, HUMAN; TUBULIN;

ADULT; AGED; ARTICLE; BLADDER TUMOR; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; TUBULIN; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84897090650     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0993-z     Document Type: Article

References (29)

1. Saxman SB, Propert KJ, Einhorn LH et al (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15: 2564-2569.
2. Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42: 50-54.
3. von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608.
4. Bellmunt J, Theodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27: 4454-4461.
5. Wilson L, Jordan MA (1995) Microtubule dynamics: taking aim at a moving target. Chem Biol 2: 569-573.
6. Luduena RF (1998) Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 178: 207-275.
7. Sullivan KF (1988) Structure and utilization of tubulin isotypes. Annu Rev Cell Biol 4: 687-716.
8. Panda D, Miller HP, Banerjee A et al (1994) Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA 91: 11358-11362.
9. Ferrandina G, Zannoni GF, Martinelli E et al (2006) Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12: 2774-2779.
10. Katsetos CD, Herman MM, Mork SJ (2003) Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 55: 77-96.
11. Portyanko A, Kovalev P, Gorgun J et al (2009) beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion. Virchows Arch 454: 541-548.
12. Gan PP, Kavallaris M (2008) Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity. Cancer Res 68: 9817-9824.
13. Kamath K, Wilson L, Cabral F et al (2005) BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280: 12902-12907.
14. Seve P, Isaac S, Tredan O et al (2005) Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11: 5481-5486.
15. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) Pathology and genetics of tumours of the urinary system and male genital organs. IARCPress, Lyon, pp 90-123.
16. Edge SB (2010) AJCC Cancer Staging Manual. Springer, Chicago, pp 497-505.
17. Simon R, Mirlacher M, Sauter G (2003) Tissue microarrays in cancer diagnosis. Expert Rev Mol Diagn 3: 421-430.
18. Ohishi Y, Oda Y, Basaki Y et al (2007) Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol 105: 586-592.
19. Giannakakou P, Sackett DL, Kang YK et al (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118-17125.
20. Kavallaris M, Kuo DY, Burkhart CA et al (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282-1293.
21. Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194-204.
22. Berrieman HK, Lind MJ, Cawkwell L (2004) Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 5: 158-164.
23. Cullen KJ, Schumaker L, Nikitakis N et al (2009) beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol 27: 6222-6228.
24. McCarroll JA, Gan PP, Liu M et al (2010) betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res 70: 4995-5003.
25. Pentheroudakis G, Batistatou A, Kalogeras KT et al (2011) Prognostic utility of beta-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat 127: 179-193.
26. Verdier-Pinard P, Pasquier E, Xiao H et al (2009) Tubulin proteomics: towards breaking the code. Anal Biochem 384: 197-206.
27. Hammond JW, Cai D, Verhey KJ (2008) Tubulin modifications and their cellular functions. Curr Opin Cell Biol 20: 71-76.
28. Freedman H, Huzil JT, Luchko T et al (2009) Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity. J Chem Inf Model 49: 424-436.
29. Schnaeker EM, Ossig R, Ludwig T et al (2004) Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Cancer Res 64: 8924-8931.